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BACKGROUND
Familial chylomicronemia syndrome is a rare genetic disorder that is caused by loss 
of lipoprotein lipase activity and characterized by chylomicronemia and recurrent epi-
sodes of pancreatitis. There are no effective therapies. In an open-label study of three 
patients with this syndrome, antisense-mediated inhibition of hepatic APOC3 mRNA 
with volanesorsen led to decreased plasma apolipoprotein C-III and triglyceride levels.
METHODS
We conducted a phase 3, double-blind, randomized 52-week trial to evaluate the 
safety and effectiveness of volanesorsen in 66 patients with familial chylomicronemia 
syndrome. Patients were randomly assigned, in a 1:1 ratio, to receive volanesorsen or 
placebo. The primary end point was the percentage change in fasting triglyceride 
levels from baseline to 3 months.
RESULTS
Patients receiving volanesorsen had a decrease in mean plasma apolipoprotein C-III 
levels from baseline of 25.7 mg per deciliter, corresponding to an 84% decrease at 
3 months, whereas patients receiving placebo had an increase in mean plasma apoli-
poprotein C-III levels from baseline of 1.9 mg per deciliter, corresponding to a 6.1% 
increase (P<0.001). Patients receiving volanesorsen had a 77% decrease in mean triglyc-
eride levels, corresponding to a mean decrease of 1712 mg per deciliter (19.3 mmol per 
liter) (95% confidence interval [CI], 1330 to 2094 mg per deciliter [15.0 to 23.6 mmol 
per liter]), whereas patients receiving placebo had an 18% increase in mean triglycer-
ide levels, corresponding to an increase of 92.0 mg per deciliter (1.0 mmol per liter) 
(95% CI, −301.0 to 486 mg per deciliter [–3.4 to 5.5 mmol per liter]) (P<0.001). At 
3 months, 77% of the patients in the volanesorsen group, as compared with 10% of 
patients in the placebo group, had triglyceride levels of less than 750 mg per deciliter 
(8.5 mmol per liter). A total of 20 of 33 patients who received volanesorsen had injection-
site reactions, whereas none of the patients who received placebo had such reactions. 
No patients in the placebo group had platelet counts below 100,000 per microliter, 
whereas 15 of 33 patients in the volanesorsen group had such levels, including 2 who 
had levels below 25,000 per microliter. No patient had platelet counts below 50,000 
per microliter after enhanced platelet-monitoring began.
CONCLUSIONS
Volanesorsen lowered triglyceride levels to less than 750 mg per deciliter in 77% of 
patients with familial chylomicronemia syndrome. Thrombocytopenia and injection-
site reactions were common adverse events. (Funded by Ionis Pharmaceuticals and 
Akcea Therapeutics; APPROACH Clinical Trials.gov number, NCT02211209.)
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Familial chylomicronemia syndrome is a rare genetic disorder characterized by reduced or absent lipoprotein lipase (LPL) 
activity.1-4 LPL mediates lipolysis of plasma triglyc-
erides in chylomicrons and other triglyceride-rich 
lipoproteins,5 and its absence leads to marked 
fasting and postprandial chylomicronemia, with 
triglyceride levels 10 to 100 times above the nor-
mal level of 150 mg per deciliter (1.7 mmol per 
liter). Familial chylomicronemia syndrome results 
from inactivating mutations in both alleles of the 
LPL gene or from mutations in other genes encod-
ing proteins required for LPL activity, such as apo-
lipoproteins C-II and A-5 (APOC2 and APOA5), 
glycosylphosphatidylinositol-anchored high-density 
lipoprotein binding protein 1 (GPIHBP1), and lipase 
maturation factor 1 (LMF1).6-8 Occasionally, pa-
tients with familial chylomicronemia syndrome 
phenotypes do not present with mutations in these 
genes.9,10 Patients with this syndrome may exhibit 
eruptive xanthoma, lipemia retinalis, and hepato-
splenomegaly and may have recurrent episodes of 
abdominal pain and acute pancreatitis.11 Although 
lipoprotein apheresis can lower greatly elevated 
triglyceride levels in the short term, the only cur-
rent long-term therapy is restriction of total fat in-
take to less than 10 to 15% of daily calories (15 to 
20 g per day), which is often ineffective in prevent-
ing chylomicronemia and acute pancreatitis.2,3,11,12
Elevated plasma levels of apolipoprotein C-III 
are a major risk factor for hypertriglyceridemia.13-15 
Previously, it was thought that apolipoprotein 
C-III raised plasma triglyceride levels primarily 
by inhibiting LPL activity. However, in a recent 
pilot study in three patients with familial chylo-
micronemia syndrome, plasma apolipoprotein 
C-III levels were reduced by antisense targeting 
of hepatic APOC3 mRNA with volanesorsen, which 
led to reductions in triglyceride levels of 56 to 
86%, findings that support the hypothesis that 
apolipoprotein C-III also inhibits an LPL-inde-
pendent pathway of triglyceride-rich lipoprotein 
clearance.16 These preliminary results led us to 
conduct the APPROACH trial, a 52-week placebo-
controlled trial of volanesorsen-mediated inhibi-
tion of plasma apolipoprotein C-III in 66 patients 
with familial chylomicronemia syndrome.
Me thods
Trial Design
The APPROACH trial was a randomized, double-
blind, phase 3 trial that evaluated the efficacy 
and safety of volanesorsen sodium (at a dose of 
300 mg subcutaneously once a week) as com-
pared with placebo in patients older than 18 years 
of age who had familial chylomicronemia syn-
drome. Patients were eligible to participate if the 
syndrome was confirmed either by genetic test-
ing or by documentation of low LPL activity 
(levels <20% of the normal range) and if fasting 
triglyceride levels were at or above 750 mg per 
deciliter (8.5 mmol per liter). Genetic confirma-
tion of the syndrome was based on detection of 
homozygosity, compound heterozygosity, or dou-
ble heterozygosity for known loss-of-function 
mutations in LPL, APOC2, APOA5, GPIHBP1, or LMF1 
genes. Alternatively, patients were eligible if their 
post-heparin LPL activity, measured in a central 
laboratory, was less than 20% of the normal 
range. Enrollment of patients without a docu-
mented history of previous pancreatitis was 
capped at 28% of the total cohort.
After a 6-week diet stabilization run-in period 
during which patients were asked to follow a 
diet that included less than 20 g of fat per day, 
patients with fasting baseline triglyceride levels 
of 750 mg per deciliter or higher were randomly 
assigned in a 1:1 ratio to volanesorsen at a dose 
of 300 mg per week or placebo, with stratifica-
tion according to history or no history of pan-
creatitis and according to receipt or no receipt of 
concurrent fibrates, prescription n−3 fatty acids, 
or both. Volanesorsen or placebo was adminis-
tered as a single subcutaneous injection once a 
week for 52 weeks. During the trial, a reduction 
of dosing to once every other week was allowed 
if unacceptable side effects or adverse events oc-
curred. The primary end point was the percent-
age change in fasting triglyceride levels from 
baseline to the time the primary analysis was 
performed at the end of month 3; the fasting 
triglyceride level for month 3 was the average of 
fasting assessments made at week 12 (day 78) 
and week 13 (day 85).
Trial Oversight
We conducted the trial at 40 centers in 12 coun-
tries from August 2014 through March 2017. The 
protocol was approved by the institutional review 
board at each participating center and by an ethics 
committee (Quorum Review IRB), and the trial 
was performed in accordance with the principles 
of the Declaration of Helsinki and current Good 
Clinical Practice guidelines. All patients provided 
written informed consent before enrollment.
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We assessed safety by determining the inci-
dence, severity, and dose relationship of adverse 
events and changes in laboratory measurements. 
Episodes of acute pancreatitis were evaluated for 
safety and independently adjudicated according 
to the revised Atlanta criteria.17 Further details 
on evaluations of safety are provided in the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org.
The trial was designed and conducted, and 
the data analyzed, by the sponsors (Ionis Pharma-
ceuticals and Akcea Therapeutics). All the authors 
interpreted the data and collaborated in the 
preparation of the manuscript. The first draft of 
the manuscript and all revisions were written by the 
first author with assistance from two coauthors 
employed by Ionis Pharmaceuticals and were 
reviewed by all the authors. All the authors ap-
proved the final version, made the decision to 
submit the manuscript for publication, vouch for 
the completeness and accuracy of the data, and 
affirm that the trial was conducted and reported 
with fidelity to the protocol and statistical analy-
sis plan (available at NEJM.org). Additional de-
tails on the methods are provided in the Supple-
mentary Appendix.
Statistical Analysis
The primary end point was the percentage change 
in fasting triglyceride levels from baseline to 
month 3 among patients who received volane-
sorsen as compared with patients who received 
placebo in the full analysis set. The data were 
evaluated with the use of an analysis of covari-
ance (ANCOVA) model, with two randomization 
stratification factors (presence or absence of his-
tory of pancreatitis and receipt or no receipt of 
concurrent n−3 fatty acids, fibrates, or both) 
along with the treatment group as a factor and 
log-transformed baseline triglyceride levels as a 
covariate. For the primary analysis end point at 
3 months, there were no missing data on triglyc-
eride levels. All patients had triglyceride levels 
measured at either week 12 or week 13, and 76% 
had triglyceride levels measured at both visits. 
The primary end point at 3 months was defined 
as the average of levels at week 12 and week 13 
for patients who had triglyceride data recorded 
at both weeks; for patients who had triglyceride 
levels measured at only one of these two visits, 
that level was used.
Nine secondary end points were prespecified 
and prioritized by rank to be analyzed in hierar-
chical order (details are provided in the Supple-
mentary Appendix). If analysis of the first end 
point showed significance, the second end point 
in the hierarchy would be tested for significance, 
and so on. If a test of an end point was nonsig-
nificant, analysis of all subsequent end points 
in the hierarchy would be considered to be ex-
ploratory.
The percentage changes from baseline to 
6 months and to 12 months were compared 
between treatment groups with the use of an 
ANCOVA model similar to that of the primary 
analysis; in these analyses, missing triglyceride 
data were imputed with the multiple imputation 
method (details are available in the Supplemen-
tary Appendix). We also performed analyses, not 
prespecified in the protocol, of the reduction in 
triglyceride levels at 6 months and 12 months 
using the observed data for various patient sub-
groups, such as a subgroup defined according to 
whether patients received full doses or reduced 
doses of volanesorsen. All statistical tests were 
conducted with two-sided tests at 5% type 1 error 
rates.
Exploratory analyses of other lipid and lipo-
protein results to investigate the difference be-
tween treatment groups in the percentage change 
from baseline to 3 months were performed with 
ANCOVA models similar to those used for the 
primary analysis.
R esult s
Characteristics of the Patients
A total of 130 patients were screened, and 67 
patients underwent randomization from Decem-
ber 2014 through January 2016. One patient as-
signed to the placebo group withdrew from the 
trial before receiving the placebo and is not in-
cluded in this analysis (Fig. S1 in the Supple-
mentary Appendix). A full description of the 
population was published previously.18 Selected 
baseline characteristics of the 66 remaining pa-
tients who underwent randomization are shown 
in Table 1, and in Table S1 in the Supplementary 
Appendix. Of the 66 patients, 41 were homozy-
gous or compound heterozygous for at least one 
of 25 different inactivating mutations in LPL, 
and 11 patients had biallelic mutations in acces-
sory proteins or were double heterozygous for 
LPL and APOA5 or LMF1 mutations; 14 patients 
did not have defined mutations but were en-
rolled on the basis of their clinical phenotype 
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and low LPL activity. A detailed description of 
the genetic diagnoses and associated phenotypes 
was published previously.19
Patients were 20 to 75 years of age, 80% were 
white, and 55% (36 patients) were women; the 
mean (±SD) body-mass index (the weight in kilo-
grams divided by the square of the height in 
meters) was 25.0±5.7. The investigator-reported 
age at which familial chylomicronemia syndrome 
was diagnosed (data available for 46 patients) 
ranged from 1 year or younger to 75 years of age. 
The syndrome was diagnosed in 6 of the pa-
tients in the first 5 years of life and in 14 in the 
first 20 years of life. Lipemia retinalis occurred 
in 14 (21%) and eruptive xanthomata in 15 (23%) 
of the 66 patients. At the time of screening, 50 
patients (76%) had a documented history of acute 
pancreatitis, and of these, 23 patients had had a 
total of 53 adjudicated episodes of acute pancre-
atitis in the previous 5 years. Seven patients had 
chronic pancreatitis. At baseline, 35 of the 66 
patients (53%) were taking fibrates, n−3 fatty 
acids, or both, and 13 (20%) were receiving 
statins. Seven patients (11%) had been treated 
with alipogene tiparvovec more than 2 years 
before they were enrolled. There were no signifi-
cant differences in baseline triglyceride levels 
between patients who were receiving lipid-lower-
ing medication and those who were not. Mean 
fasting triglyceride levels were elevated — 
2209±1199 mg per deciliter (25.0±13.6 mmol 
per liter; normal level, <150 mg per deciliter 
[<1.7 mmol per liter]) — as were mean chylomi-
cron triglyceride levels (1849±1176 mg per deci-
liter [20.9±13.3 mmol per liter]; normally not 
present) and mean apolipoprotein B-48 levels 
(10.2±6.6 mg per deciliter [normal level, <0.83 
mg per deciliter]). Mean plasma apolipoprotein 
C-III levels were 30.2±14.2 mg per deciliter (nor-








Mean age (range) — yr 46 (20–68) 47 (22–75) 46 (20–75)
Sex — no.
Female 19 17 36
Male 14 16 30
Body-mass index† 24.1±4.7 25.9±6.5 25.0±5.7
Triglycerides — mg/dl 2152 2267 2209
History of pancreatitis — no. (%) 26 (79) 24 (73) 50 (76)
Baseline use of n−3 fatty acids, fibrates,  
or both — no. (%)
16 (48) 19 (58) 35 (53)
Genetic mutations — no. (%)
LPL 24 (73) 17 (52) 41 (62)
APOA5 1 (3) 1 (3) 2 (3)
GPIHBP1 0 5 (15) 5 (8)
LMF1 0 1 (3) 1 (2)
APOC2 0 1 (3) 1 (2)
LPL/LMF-1 0 1 (3) 1 (2)
LPL/APOA5 1 (3) 0 1 (2)
Not identified‡ 7 (21) 7 (21) 14 (21)
*  Plus-minus values are means ±SD. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. 
APOA5 denotes apoprotein A-5, APOC2 apoprotein C-II, GPIHBP1 glycosylphosphatidylinositol-anchored high-density–
lipoprotein-binding protein 1, LMF-1 lipase maturation factor 1, and LPL lipoprotein lipase.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Among 14 patients with genetic mutations that were not identified, 6 had mutations in LPL or accessory proteins not 
annotated or predicted to be inactivating, and 5 had no known relevant mutations. Genetic testing was not performed 
in 3 patients because of lack of consent; these patients were enrolled on the basis of other criteria.
Table 1. Characteristics of the Patients at Baseline.*
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Efficacy End Points
Effects on Plasma Apolipoprotein C-III  
and Triglyceride Levels
Volanesorsen reduced mean apolipoprotein C-III 
levels from baseline by 84% after 3 months of 
therapy and by 83% after 6 months of therapy 
(P<0.001 for both comparisons), which corre-
sponded to decreases of 25.7 mg per deciliter 
and 25.6 mg per deciliter, respectively; in con-
trast, mean apolipoprotein C-III levels increased 
by 6.1% (1.9 mg per deciliter) after 3 months of 
therapy and decreased by 5.2% (1.7 mg per deci-
liter) at 6 months among patients who received 
placebo (Table 2 and Fig. 1A). With respect to 
the primary efficacy end point, the mean per-
centage change in triglyceride levels between 
baseline and 3 months was a decrease of 77% in 
the volanesorsen group, as compared with an 
18% increase in the placebo group (P<0.001) 
(Table 2), which corresponded to a mean de-
crease of 1712 mg per deciliter (19.3 mmol per 
liter) (95% confidence interval [CI], 1330 to 2094 
mg per deciliter [15.0 to 23.6 mmol per liter]) in 
the volanesorsen group, as compared with an 
increase of 92.0 mg per deciliter (1.0 mmol per 
liter) (95% CI, –301 to 486 mg per deciliter [–3.4 
to 5.5 mmol per liter]) in the placebo group 
(P<0.001) (Fig. 2).
Secondary Efficacy End Points
The results of the analysis of the first-ranked 
secondary end point — treatment response rate, 
with response defined as a fasting plasma triglyc-
eride level of less than 750 mg per deciliter at 
3 months — were significant. A waterfall plot of 
results at 3 months (Fig. S2 in the Supplemen-
tary Appendix) shows that 77% of patients treated 
with volanesorsen, as compared with 10% of 
patients who received placebo, achieved triglyc-
eride levels below 750 mg per deciliter (odds 
ratio, 186.16; 95% CI, 12.86 to could not be 
estimated; P<0.001). The result of the second-
ranked secondary end point — the percentage 
change in fasting triglyceride levels from base-
line to 6 months — was also significant. Volane-
sorsen treatment effects were sustained for 
6 months, at which time triglyceride levels were 
lower by a mean of 53% in the volanesorsen 
group (decrease, 1380 mg per deciliter [15.6 mmol 
per liter]), as compared with a 25% mean in-
crease in the placebo group (increase, 224 mg 
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between-group difference in the percentage 
change was −77.8% (95% CI, −106.4 to −49.1; 
P<0.001).
The result of the analysis of the third-ranked 
secondary end point — the percentage change 
in fasting triglyceride levels from baseline to 12 
months — was significant. At 12 months, triglyc-
eride levels were reduced by 40% in the volane-
sorsen group (decrease, 986 mg per deciliter 
[11.1 mmol per liter]), whereas the levels at 12 
months were increased by 9% in the placebo 
group (increase, 39 mg per deciliter [0.44 mmol 
per liter]). The between-group relative difference 
in percentage change was −49.1% (95% CI, −94.7 
to −3.5; P = 0.03). The result of the analysis of the 
fourth-ranked secondary end point, the average 
of maximum intensity of patient-reported ab-
dominal pain during the treatment period, did 
not reach statistical significance. Descriptions 
and results of exploratory analyses of the other 
secondary end points, which are also considered 
to be nonsignificant, are provided in the Supple-
mentary Appendix.
Figure 1A and 1B shows the mean percentage 
change in apolipoprotein C-III and plasma tri-
glyceride levels over the full 52-week trial among 
all patients who underwent randomization. Of 
the patients who received volanesorsen, 19 com-
pleted the full 52-week treatment period: 6 re-
ceived the starting dose (300 mg per week) for 
the entire treatment period, and among the re-
maining 13, doses were reduced in frequency (to 
300 mg every 2 weeks), treatment was paused, or 
both. Figure 1C shows the results of an analysis, 
not prespecified in the protocol, of the mean 
percentage change in triglyceride levels among 
patients who had volanesorsen dose adjustments 
Figure 1 (facing page). Changes in Fasting Apolipoprotein 
C-III and Triglyceride Levels.
Panel A shows the change in levels of apolipoprotein 
C-III over the 52-week treatment period among patients 
who were randomly assigned to receive volanesorsen 
at a dose of 300 mg per week and those who were as-
signed to receive placebo. Panel B shows the percent-
age change in triglyceride levels over the 52-week trial 
for all patients. Panel C shows the percentage change 
in triglyceride levels among patients in the volanesorsen 
group who had a dose reduction during the 52-week 
trial and those who did not have a dose reduction dur-
ing the trial, as well as in patients who did not complete 
the trial. Data presented are means; I bars indicate 
standard errors.
Figure 2. Change in Triglyceride Levels in Patients at 3 Months.
Panel A shows the percentage change in triglyceride levels from baseline to 3 months (the primary end point) 
among patients receiving placebo and those receiving volanesorsen at a dose of 300 mg per week. Panel B shows 
the reductions in those levels in milligrams per deciliter. To convert the values for triglycerides to millimoles per 
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and those whose doses were not adjusted. Among 
the 6 patients who did not have a dose reduction, 
the mean decrease in triglyceride levels from base-
line was 79% at 3 months, 80% at 6 months, and 
72% at 12 months (mean decreases from baseline 
of 1670 mg per deciliter [18.9 mmol per liter], 
1656 mg per deciliter [18.7 mmol per liter], and 
1454 mg per deciliter [16.4 mmol per liter], respec-
tively), whereas corresponding decreases in triglyc-
eride levels among the 13 patients whose doses 
were reduced was 71% at 3 months, 52% at 
6 months, and 54% at 12 months (mean decrease 
from baseline of 1933 mg per deciliter [22.5 mmol 
per liter], 1564 mg per deciliter [17.7 mmol per 
liter], and 1400 mg per deciliter [15.8 mmol per 
liter], respectively). Among the 6 patients whose 
doses were not reduced, 5 had triglyceride levels 
below 750 mg per deciliter at 6 months, and 4 had 
triglyceride levels below 750 mg per deciliter at 
12 months. Of the 13 patients whose doses were 
reduced, 6 had triglyceride levels below 750 mg 
per deciliter at 6 months, and 6 had triglyceride 
levels below 750 mg per deciliter at 12 months; 
3 patients had triglyceride levels below 750 mg 
per deciliter at both 6 and 12 months.
Exploratory Analyses
Table 2 shows an analysis of the effects of volane-
sorsen at 3 months on other lipoprotein and apo-
protein variables. Patients who received volane-
sorsen had decreases in levels of chylomicron 
triglyceride (by 83%), apolipoprotein B-48 (by 76%), 
non–high-density lipoprotein (HDL) cholesterol 
(by 46%), and very-low-density lipoprotein (VLDL) 
cholesterol (by 58%) and increases in levels of 
HDL cholesterol (by 46%), apolipoprotein A1 (by 
14%), low-density lipoprotein (LDL) cholesterol 
(by 136%), and total apolipoprotein B (by 20%).
Volanesorsen lowered triglyceride levels ir-
respective of the patients’ genetic diagnoses. At 
3 months, mean triglyceride levels were decreased 
by 65% in the 17 patients with biallelic muta-
tions in LPL and by 75% in the 9 patients with 
non-LPL genetic deficiencies. Patients with muta-
tions in APOC2, GPIHBP1, APOA5, and LMF1 all 
showed marked triglyceride decreases (by 69 to 
88%). Treatment was also effective irrespective 
of baseline triglyceride levels and was equally 
effective in patients receiving baseline n−3 fatty 
acids, fibrate therapy, or both and patients not 
receiving those therapies (mean decrease from 
baseline to 3 months, 76% [95% CI, 42 to 110] 
and 73% [95% CI, 50 to 96], respectively).
Because the size of the trial was limited by 
the low prevalence of familial chylomicronemia 
syndrome, a change in the number of episodes 
of acute pancreatitis during the trial was not a 
prescribed efficacy end point. However, in ex-
ploratory analyses, we assessed adjudicated epi-
sodes of acute pancreatitis that occurred during 
the trial. During the treatment period, three pa-
tients in the placebo group had four episodes 
of acute pancreatitis, whereas one patient in 
the volanesorsen group had one episode (9 days 
after receiving the final dose).
Safety
The most common adverse events that occurred 
during treatment among patients who received 
volanesorsen were those related to injection-site 
reactions and decreases in platelet counts (Table 3, 
and Table S3 in the Supplementary Appendix). In 
the volanesorsen group, 20 patients (61%) had at 
least one injection-site reaction (categorized as 







Injection-site reaction 0 20 (61)
Platelet count decreased 1 (3) 11 (33)
Abdominal pain 7 (21) 9 (27)
Fatigue 3 (9) 7 (21)
Headache 5 (15) 7 (21)
Nausea 2 (6) 6 (18)
Asthenia 3 (9) 5 (15)
Myalgia 1 (3) 5 (15)
Diarrhea 2 (6) 5 (15)
Epistaxis 0 5 (15)
Vomiting 3 (9) 5 (15)
Nasopharyngitis 7 (21) 5 (15)
Petechiae 0 4 (12)
Arthralgia 0 4 (12)
Pain in extremity 1 (3) 4 (12)
Thrombocytopenia 0 4 (12)
Diabetes mellitus 0 4 (12)
*  Shown are adverse events that were reported in 10% or more of the patients 
and were more common in the volanesorsen group than in the placebo group.
Table 3. Adverse Events.*
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volanesorsen injections, as compared with 0% 
of placebo injections, were associated with these 
reactions. One patient withdrew from the trial 
early owing to an injection-site reaction (Table S3 
in the Supplementary Appendix).
Confirmed nadir platelet counts below the 
normal level of 140,000 per microliter were ob-
served in 25 patients (76%) in the volanesorsen 
group and in 8 patients (24%) in the placebo 
group; confirmed nadir levels below 100,000 per 
microliter were observed in 16 patients (48%) who 
received volanesorsen but in no patients who re-
ceived placebo (Table 4). Because there was no 
documented history of marked decreases in plate-
let counts in humans treated with antisense drugs 
of this class,20 the initial protocol required plate-
let monitoring at 4-to-6-week intervals. However, 
midway through the trial (May 2016), grade 4 
thrombocytopenia (<25,000 platelets per micro-
liter) developed in two patients in the volane-
sorsen group, and their trial treatment was dis-
continued. No major bleeding events occurred in 
either patient, and the two patients reached nor-
mal platelet counts 23 and 33 days after discon-
tinuation of the drug. One patient received oral 
prednisone at a dose of 60 mg for 23 days. The 
other patient received methylprednisolone at a 
dose of 125 mg for 11 days, followed by oral 
prednisone at a dose of 70 mg tapered to 50 mg 
for 21 days, as well as intravenous immune 
globulin at a dose of 60 g and 80 g on 2 succes-
sive days, followed 4 days later by immune 
globulin at a dose of 40 g daily for 5 more days. 
Three other patients with lesser grades (grade 
1 or 2) of decreased platelet counts were with-
drawn from the trial because of concerns on the 
part of the site investigators.
After the two cases of severe thrombocytope-
nia occurred, a more intensive platelet monitor-
ing program was implemented that consisted 
of assessment of platelet counts every 2 weeks, 
a threshold (<100,000 per microliter) for reduc-
tion in dose frequency to every 2 weeks, and a 
new threshold (75,000 per microliter, changed 
from 50,000 per microliter) for an interruption 
in dosing. After these rules were implemented, no 
patients had platelet-count declines to less than 
50,000 per microliter, and no platelet-related 
dose discontinuations occurred. Dose reduction 
of volanesorsen occurred in 13 patients; dose 
reductions in 9 of those patients occurred be-
cause of decreases in platelet counts.
Fourteen patients assigned to volanesorsen, 
as compared with 2 patients assigned to placebo, 
did not complete the 52-week trial (Fig. S1 in the 
Supplementary Appendix). Among the patients 
treated with volanesorsen, 9 discontinued the 
trial because of adverse events that occurred 
during treatment — 5 because of platelet de-
creases and 4 because of other volanesorsen-
related effects (one each because of an injection-
site reaction and fatigue; fatigue; chills and 
sweating; and generalized erythema). Four pa-
tients in the volanesorsen group voluntarily with-
drew from the trial (reasons provided were de-
hydration, uncertainty of drug efficacy, travel 
schedule, and duration of trial visits), and one 
patient was withdrawn by an investigator for 
nonadherence. Among patients in the placebo 
group, one patient had been erroneously assigned 
to that group and did not receive the assigned 
placebo, and one patient withdrew for reasons 
not related to adverse events that occurred dur-
ing the treatment period. There were no deaths 
during the trial.
Discussion
The APPROACH trial showed that volanesorsen-
mediated lowering of plasma apolipoprotein C-III 
levels in patients with familial chylomicronemia 
syndrome effectively lowered plasma triglycerides 






no. of patients (before/after)†
<140,000/μl 8 (4/4) 25 (15/10)
<100,000/μl 0 16 (10/6)
100,000 to <140,000/μl 8 (4/4) 9 (5/4)
75,000 to <100,000/μl 0 6 (2/4)
50,000 to <75,000/μl 0 7 (5/2)
25,000 to <50,000/μl 0 1 (1/0)
0 to <25,000/μl 0 2 (2/0)‡
*  No patients had a major bleeding event.
†  Shown are numbers of patients who had the indicated platelet level during the 
trial; “before/after” indicates the numbers of patients who had that level before 
and after enhanced platelet monitoring was implemented.
‡  Platelet counts in both patients normalized after treatment was discontinued 
and glucocorticoids (and intravenous immune globulin in one patient) were 
administered.
Table 4. Platelet Counts before and after Enhanced Platelet Monitoring.
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(8.5 to 10 mmol per liter) that has been associ-
ated with triglyceride-induced acute pancreati-
tis.6,21-26 Although the mean LDL cholesterol level 
increased from 28 to 61 mg per deciliter (136%), 
the mean baseline level of LDL cholesterol was 
very low. Moreover, non–HDL cholesterol, a gen-
eral measure of atherogenic lipoproteins, decreased 
by 45%. These data show that volanesorsen-
mediated lowering of apolipoprotein C-III effec-
tively enhances clearance of triglyceride-rich lipo-
proteins in patients without LPL activity.27 Because 
traditional triglyceride-lowering therapies such 
as fibrates, n−3 fatty acids, and statins depend 
on LPL activity, inhibition of hepatic VLDL out-
put, or both, they are largely ineffective in famil-
ial chylomicronemia syndrome, as evidenced by 
the fact that half the patients in this trial were 
receiving one or more of these agents at the time 
they were recruited.12
Although patients with familial chylomicro-
nemia syndrome have many physical and cogni-
tive complications from sustained chylomicrone-
mia,3,11,28,29 potentially recurrent and even fatal 
acute pancreatitis is the complication that is 
most feared. The reported prevalence of acute 
pancreatitis among patients with this syndrome 
is not known with certainty but may be as high 
as 67%,29 with an associated risk of major com-
plications that is two or three times as high as 
the risk among patients with pancreatitis with-
out hypertriglyceridemia, as well as an associated 
6% risk of death from acute pancreatitis.26,29,30 
Maintaining triglyceride levels below 750 mg per 
deciliter would be expected to decrease the risk 
for pancreatitis. Although the small size of the 
APPROACH trial did not allow us to draw firm 
conclusions about the effect of volanesorsen on 
pancreatitis, we performed an exploratory analy-
sis of the effect of volanesorsen on patients with 
multiple previous occurrences of acute pancre-
atitis, since these patients are known to be at 
greater risk for subsequent episodes.24,31-33 There 
were 11 patients with two or more adjudicated 
episodes of acute pancreatitis in the previous 
5 years, with a total of 41 previous episodes 
(Table S4 in the Supplementary Appendix). Of 
those 11 patients, 4 were assigned to placebo; 
3 of the 4 in the placebo group had four epi-
sodes of acute pancreatitis. No episodes of acute 
pancreatitis occurred among the 7 patients who 
received volanesorsen. Observational data sug-
gest that the incidence of acute pancreatitis in-
creases approximately 3% for every increment of 
100 mg per deciliter in triglyceride levels over 
1000 mg per deciliter34; we would therefore 
speculate that a decrease in triglyceride levels to 
any extent below this threshold would result in 
a decrease in the risk of acute pancreatitis.
Volanesorsen therapy was associated with 
mild-to-moderate injection-site reactions (in 12% 
of injections). One patient withdrew from the 
trial owing to these reactions. Another side ef-
fect was thrombocytopenia, which was defined 
as a platelet count below 140,000 per microliter. 
A recently reported natural history study of 87 
patients with familial chylomicronemia syndrome 
over a 15-year period indicates considerable labil-
ity in platelet counts: 55.2% had thrombocytope-
nia on at least one occasion, and 2.4% had 
platelet levels of less than 50,000 per microliter, 
whereas 12.6% presented with thrombocytosis.35 
During the APPROACH trial, 8 patients (24%) in 
the placebo group and 25 (76%) in the volane-
sorsen group had platelet-level decreases to be-
low 140,000 per microliter. Before the initiation 
of the APPROACH trial, more than 2600 patients 
had been treated with 16 different 2′-O-methoxy-
ethyl (2′MOE) antisense agents (the class of drugs 
to which volanesorsen belongs) in placebo-con-
trolled and open-label clinical trials, with treat-
ment durations as long as 4.6 years. There was 
no evidence of a class effect on platelet counts 
and no incidence of confirmed platelet levels 
below 50,000 per microliter.20 Thus, platelet mon-
itoring in APPROACH was initially performed at 
4-to-6-week intervals; however, because platelet 
counts of less than 25,000 per microliter devel-
oped in 2 patients, a more intensive platelet-
monitoring protocol was instituted. After im-
plementation of these rules, there were no 
platelet-level declines to less than 50,000 per mi-
croliter and no platelet-related discontinuations 
of volanesorsen in the trial. The underlying 
mechanisms responsible for the declines in plate-
let levels are not clear at present. Nearly all the 
patients received an injection of heparin at the 
beginning of the trial and at approximately 26 
weeks to enable measurement of LPL activity, but 
a classic heparin-induced mechanism for throm-
bocytopenia was excluded, as were antisense-
mediated effects on platelet production. There 
was some evidence for associated immunologic 
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response in the most severe events. It is impor-
tant to note that decreases in platelet levels were 
reversible with an interruption in dosing, and for 
the most part appeared to be dose-dependent. 
The establishment of more frequent platelet 
monitoring and either an interruption in dosing 
or reductions in the dose, or both, appeared to 
be adequate for preventing severe thrombocyto-
penia and maintaining stable platelet counts for 
most patients.
Fourteen patients in the volanesorsen group 
discontinued the trial: 9 because of adverse 
events that occurred during treatment (including 
5 who had decreases in platelet counts and 
4 because of other drug-related side effects), 
and 5 primarily because of issues related to re-
quirements of the protocol. The combination of 
an unexpected, potentially serious level of throm-
bocytopenia occurring during the trial and the 
lack of a prespecified protocol for responding to 
it in a timely manner led to patient and investi-
gator uncertainty and resulted in patients with-
drawing from the trial.
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